

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#18/B  
YC  
12-1802

In re patent application of  
Ralph M. ELLISON *et al.*



Atty. Docket No: 077319/0225

Serial No.: 09/173,531

Group Art Unit: 1616

Filed: October 15, 1998

Examiner: J. Pak

For: **COMPOSITIONS AND METHODS FOR THE TREATMENT OF PRIMARY  
AND METASTATIC NEOPLASTIC DISEASES USING ARSENIC  
COMPOUNDS**

AMENDMENT AND REQUEST FOR  
RECONSIDERATION UNDER 37 CFR §1.111

**RECEIVED**

NOV 29 2002

Commissioner for Patents  
Washington, D.C. 20231

TECH CENTER 1600/2900

Sir:

In response to the Official Action mailed June 25, 2002, the period for response to which has been extended to expire on November 25, 2002, by virtue of the accompanying petition and fee, applicants request that the PTO amend the above-identified application, as indicated below, and reconsider this case in light of the following remarks.

IN THE CLAIMS

Please cancel claims 3, 13 and 18 and enter the following amended versions of claims 1, 2, 9, and 14-17 into the record.

1. (Amended) A method of treatment of solid tumors in a human in need of such treatment, which comprises administering a therapeutically effective amount of one or more arsenic compounds, or a prodrug of one or more of said arsenic compounds, to said human, wherein said solid tumor is a tumor of the breast, colon, ovary, kidney, central nervous system, bladder, prostate or lung.